Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Celgene's New Regime: Hugin And Alles Discuss Handing Over The Reins

This article was originally published in Scrip

Executive Summary

Mark Alles has been in his first pharma chief executive role for six weeks, after stepping into former Celgene Corp. leader Bob Hugin's shoes in March. While Alles has been with the company for 12 years and in the pharma industry for three decades he brings new skills to the top spot at Celgene and a keen eye for keeping science at the fore of his corporate decision making.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC065004

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel